Abstracts tagged "Gene Expression"

Abstract Number: 1416 • 2017 ACR/ARHP Annual Meeting
Higher Expression of Type 1 Interferon in Synovitis of Patient with Undifferentiated Arthritis before They Met Rheumatoid Arthritis Criteria Compared to Established Rheumatoid Arthritis. a Retrospective Study with 14 Years of Follow-up
Andrea Cuervo¹, Raquel Celis², Julio Ramírez³, Alicia Usategui⁴, Regina Faré⁵, M. Victoria Hernández⁶, Virginia Ruiz-Esquide³, Jose Inciarte-Mundo⁷, Raimon Sanmarti⁸, Jose L. Pablos⁹ and Juan D. Cañete⁷, ¹Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ⁴Grupo de Enfermedades Inflamatorias y Autoinmunes, Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁵Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain, ⁶Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁷Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁸Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁹Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain
Background/Purpose: Undifferentiated Arthritis (UA) is defined as an inflammatory oligo/poly arthritis that does not fulfil criteria for a definitive diagnosis.Delay in diagnosis and treatment leads…
Abstract Number: 2659 • 2017 ACR/ARHP Annual Meeting
Development of a Protocol for Single Cell Transcriptomics of Cells from Cryopreserved Lupus Nephritis Kidney Tissue and Urine for the Accelerating Medicines Partnership RA/SLE Network
Deepak Rao¹, Celine C. Berthier², Arnon Arazi³, Anne Davidson⁴, Yanyan Liu⁵, Edward Browne³, Thomas Eisenhaure³, Adam Chicoine⁶, David Lieb³, Dawn Smilek⁷, Patti Tosta⁷, James Lederer⁸, Michael Brenner⁵, David Hildeman⁹, E. Steve Woodle¹⁰, David Wofsy¹¹, Jennifer H. Anolik¹², Matthias Kretzler¹³, Nir Hacohen¹⁴ and Betty Diamond¹⁵, ¹Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Nephrology, Division of Nephrology, University of Michigan Medical Center, Ann Arbor, MI, ³Broad Institute, Cambridge, MA, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Inst for Med Rsch, Manhasset, NY, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Immune Tolerance Network, San Francisco, CA, ⁸Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁹University of Cincinnati, Cincinnati, OH, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, ¹¹Rheumatology, UCSF, San Francisco, CA, ¹²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ¹³Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, MI, ¹⁴Harvard Medical School, Boston, MA, ¹⁵Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: There is a critical need to define the cells that mediate tissue damage in lupus nephritis. Here we aimed to establish a protocol to…
Abstract Number: 405 • 2017 ACR/ARHP Annual Meeting
Dynamics of Transcriptional Signatures from Purified Synovial Macrophage Subsets during Acute and Chronic Murine Models of Inflammatory Arthritis
Philip J. Homan, Salina Dominguez, Harris Perlman, Deborah R. WInter and Carla Cuda, Department of Medicine Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) manifests in persistent synovial inflammation, cellular infiltration and pro-inflammatory cytokine production, resulting in progressive joint destruction. Macrophages have been implicated in…
Abstract Number: 1658 • 2017 ACR/ARHP Annual Meeting
Interferon Related Soluble Mediator Concentrations Significantly Correlate with Disease Activity in SLE Patients with Active Interferon Pathways
Rufei Lu¹, Cristina Arriens², Teresa Aberle³, Stan Kamp³, Melissa E. Munroe³, Tim Gross¹, Wade DeJager³, Susan Macwana³, Virginia C. Roberts³, Stephen Apel⁴, Hua Chen³, Eliza Chakravarty⁵, Katherine Thanou³, Joan T. Merrill⁶ and Judith A. James⁷, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Oklahoma Medical research af, Edmond, OK, ⁶Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose : Interferon (IFN) pathways are dysregulated in a subset of patients with systemic lupus erythematosus (SLE). IFN dysregulation likely contributes to SLE pathogenesis and…
Abstract Number: 2866 • 2017 ACR/ARHP Annual Meeting
Microarray Pathway Analysis Comparing Baricitinib and Adalimumab in Moderate to Severe Rheumatoid Arthritis Patients, from a Phase 3 Study
Paul Emery¹, Peter C. Taylor², Michael Weinblatt³, Yoshiya Tanaka⁴, Edward C. Keystone⁵, Ernst R. Dow⁶, Richard Higgs⁶, William L. Macias⁶, Guilherme Rocha⁶, Terence P. Rooney⁶, Douglas E. Schlichting⁶, Steven H. Zuckerman⁶ and Iain B. McInnes⁷, ¹Leeds MSK Biomed/Chapel Allerton Hospital, Leeds, United Kingdom, ²NDORMS, University of Oxford, Oxford, United Kingdom, ³Brigham and Women’s Hospital, Boston, MA, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵University of Toronto, Toronto, ON, Canada, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷University of Glasgow, Glasgow, United Kingdom
Background/Purpose: In RA-BEAM (NCT01710358), baricitinib (BARI), an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, yielded significant improvements in patients (pts) with…
Abstract Number: 441 • 2017 ACR/ARHP Annual Meeting
Social Media Based, Direct-to-Patient Study Designed for Development of “from Home” Testing for Rheumatoid Arthritis Patients Is Feasible and Engaged Individuals with Distinct Clinical Characteristics
Kristen Warren¹, Olga Derbeneva¹, Francisco Flores¹, Michelle Frits², James Healy¹, Christine Iannaccone³, Omar Khalid¹, Krishna Morampudi¹, Nancy Shadick⁴, Michael Weinblatt⁴, Hemani Wijesuriya¹ and Robert Terbrueggen¹, ¹DxTerity, Rancho Dominguez, CA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Physicians equipped with low cost, patient-administered, “from home” genomic tests for monitoring disease activity and therapy response could revolutionize treatment for rheumatoid arthritis…
Abstract Number: 1668 • 2017 ACR/ARHP Annual Meeting
Identification of a Serum Measure of Lupus Nephritis Activity That Detects Molecular Pathways and Mechanisms Implicated in Renal Damage
Mikhail Olferiev¹, Dina Greenman², David Fernandez¹, Kerry Merritt¹, Kyriakos A. Kirou¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Up to 60% of SLE patients develop renal involvement, and renal injury is an important predictor of mortality in patients with SLE. Kidney biopsy…
Abstract Number: 2868 • 2017 ACR/ARHP Annual Meeting
Pharmacodynamic Analysis of Whole Blood Gene Expression over 2 Years in a Phase IIIb Head-to-Head Trial of Abatacept and Adalimumab in Patients with RA
O Jabado¹, MA Maldonado¹, Michael Schiff², Michael Weinblatt³, Roy Fleischmann⁴, William H. Robinson⁵, A Greenfield¹ and SE Connolly¹, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Colorado, Denver, CO, ³Brigham and Women’s Hospital, Boston, MA, ⁴Metroplex Clinical Research Center Dallas, Dallas, TX, ⁵Stanford University, Palo Alto, CA
Background/Purpose: The head-to-head AMPLE study compared the safety and efficacy of abatacept (co-stimulatory modulator) versus adalimumab (TNFα inhibitor) for treatment of RA over 2 years.…
Abstract Number: 647 • 2017 ACR/ARHP Annual Meeting
Gene Expression in Cellular Subsets in Psoriatic Disease
Anastasiya Muntyanu¹, Fatima Abji², Remy Pollock¹, Vinod Chandran² and Dafna D Gladman², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis is an inflammatory musculoskeletal disease which develops in 30% of patients with psoriasis. Our previous peripheral blood microarray study identified CXCL10, NOTCH2NL,…
Abstract Number: 1700 • 2017 ACR/ARHP Annual Meeting
Focusing on Pulmonary Vascular Disease at Early Stage of Systemic Sclerosis: Exercise-Induced Pulmonary Arterial Hypertension and Gene Co-Expression Networks Involved in Its Pathogenesis
Yoshinobu Koyama¹, Soichiro Fuke², Yoshiharu Sato³ and Toshie Higuchi¹, ¹Center for Autoimmune Diseases, Division of Rheumatology, Japan Red Cross Okayama Hospital, Okayama, Japan, ²Department of Cardiology, Japan Red Cross Okayama Hospital, Okayama, Japan, ³DNA Chip Research Inc, Yokohama, Japan
Background/Purpose: Pulmonary arterial hypertension (PAH) is prominent as a vascular involvement in systemic sclerosis (SSc), which remains a leading cause of death in spite of…
Abstract Number: 2873 • 2017 ACR/ARHP Annual Meeting
DNA Microarray Analysis Identifies Nuclear Receptor Subfamily 4 Group a Member 2 (NR4A2) As a Novel Molecule Involved in the Pathogenesis of Sjogren’s Syndrome
Hiroyuki Takahashi, Hiroto Tsuboi, Hiromitsu Asashima, Hanae Kudo, Yuko Ono, Saori Abe, Yuya Kondo, Isao Matsumoto and Takayuki Sumida, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose:Some reports on DNA microarray analysis in labial salivary glands (LSGs) of Sjögren’s syndrome (SS) and healthy controls (HCs) showed that the genes associated with…
Abstract Number: 756 • 2017 ACR/ARHP Annual Meeting
Novel Machine Learning Classifier Accurately Predicts Intrinsic Molecular Subsets for Patients with Systemic Sclerosis
Jennifer Franks¹, Viktor Martyanov¹, Guoshuai Cai¹ and Michael L. Whitfield², ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: High-throughput gene expression profiling of skin biopsies from patients with systemic sclerosis (SSc) has identified four “intrinsic” gene expression subsets conserved across multiple cohorts…
Abstract Number: 1707 • 2017 ACR/ARHP Annual Meeting
Effect of Anabasum (JBT-101) on Gene Expression in Skin Biopsies from Subjects with Diffuse Cutaneous Systemic Sclerosis (dcSSc) and the Relationship of Baseline Molecular Subsets to Clinical Benefit in the Phase 2 Trial
Viktor Martyanov¹, Yolanda Nesbeth², Guoshuai Cai¹, Tammara A. Wood¹, Jake Reder², Scott Constantine³, Barbara White³, Robert F. Spiera⁴ and Michael L. Whitfield¹, ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Celdara Medical, LLC, Lebanon, NH, ³Corbus Pharmaceuticals, Inc., Norwood, MA, ⁴Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Anabasum (JBT-101) is a non-immunosuppressive, synthetic, CB2 agonist that resolves inflammation and fibrosis in animal models of SSc and reduces TGF-β and collagen production…
Abstract Number: 2885 • 2017 ACR/ARHP Annual Meeting
Tadalafil Reduces Skin Fibrosis and Profibrotic Genes Expression in Patients with Systemic Sclerosis
Sakir Ahmed, Mohit Kumar Rai, Durga Prasanna Misra and Vikas Agarwal, Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India
Background/Purpose: Currently, drugs that modify skin fibrosis in Systemic Sclerosis (SSc) have efficacy in certain subgroups of patients only. Phosphodiesterase-5 inhibitors (PDE5i) are known to…
Abstract Number: 764 • 2017 ACR/ARHP Annual Meeting
Application of a Novel Computational Approach to Identify New Targets and Pathways for Therapeutic Intervention in Scleroderma
Elma Kurtagic, Joel Pradines, Anthony Manning and Ishan Capila, Research, Momenta Pharmaceuticals, Inc., Cambridge, MA
Background/Purpose: Systemic Sclerosis (SSc) is a complex autoimmune disease with chronic progressive course and high interpatient variability. It is characterized by inflammation, vascular dysfunction and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].